Healthcare Providers and Services
Company Overview of Eddingpharm (Cayman) Inc.
Eddingpharm (Cayman) Inc. operates as a pharmaceuticals marketing company. The company engages in in-licensing, marketing, and distributing hospital pharmaceutical products in Hong Kong and China. It offers nutritional supplements, oncology drugs, and other pharmaceuticals. The company also offers products including Telatinib, an anti-angiogenic for gastric and solid tumors, ACTB1003, a multi-mode oral kinase inhibitor, and ACTB1010, a mitotic Aurora kinase oral inhibitor. The company has a joint venture with Chiesi Farmaceutici S.p. A to establish Chiesi Edding Hong Kong Limited. Eddingpharm (Cayman) Inc. is based in Wanchai, Hong Kong.
48/F Central Plaza
18 Harbour Road
852 2877 4866
852 2877 4966
Key Executives for Eddingpharm (Cayman) Inc.
Founder, Chairman and Chief Executive Officer
Senior Vice President of Finance
Senior Vice President of Distribution
Director of Legal Department
Compensation as of Fiscal Year 2015.
Eddingpharm (Cayman) Inc. Key Developments
Faes Farma and Eddingpharm Form Joint Venture in China
Jun 1 15
Faes Farma has signed a deal with Eddingpharm (Hong Kong) for the establishment of a joint venture that allows the Spanish company to market its products in the Chinese market. Under the terms of the agreement, the products will be manufactured in Faes Farma plants and exported to China. The project is being initiated with local development and registration of four Faes Farma products in China.
Eddingpharm (Cayman) Inc. Presents at BioEquity Europe 2015, May-20-2015 11:30 AM
Apr 10 15
Eddingpharm (Cayman) Inc. Presents at BioEquity Europe 2015, May-20-2015 11:30 AM. Venue: InterContinental Vienna, Vienna, Austria. Speakers: Xiaoming Zou, CBO.
Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa (Icosapent Ethyl) in China
Feb 26 15
Amarin Corporation plc and Eddingpharm, announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa (icosapent ethyl) in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|